drugset
Drugs / Adalimumab-EU
last change 5 days ago re-read 3 minutes ago

Adalimumab-EU

also known as Adalimumab · Humira

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 1 NCT02237729 Comparator Sep 2014 → Mar 2015 — Pfizer Completed No outcome recorded

Press releases naming this drug 227 releases

DateIssuerRelease
2026-09-28 Meitheal Pharmaceuticals, Inc. Meitheal Pharmaceuticals Announces FDA Approval of High-Concentration Formulation of YUSIMRY®, a Biosimilar to Humira® meithealpharma.com ↗
2025-10-20 AbbVie RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor abbvie.com ↗
2025-10-17 Celltrion FDA approves expanded pediatric indications for YUFLYMA® (adalimumab-aaty) and unbranded adalimumab-aaty in the United States celltrion.com ↗
2025-05-27 Organon and Co US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection organon.com ↗
2025-05-23 Celltrion Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths celltrion.com ↗
2025-04-15 Celltrion U.S. FDA grants interchangeable designation to YUFLYMA® (adalimumab-aaty), Celltrion's biosimilar to Humira® (adalimumab) celltrion.com ↗
2024-08-13 Celltrion Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program celltrion.com ↗
2024-07-18 Boehringer Ingelheim Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira® prnewswire.com ↗
2024-05-21 Alvotech Swiss AG Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. alvotech.com ↗
2024-05-20 Teva Branded Pharmaceutical Products R&D, Inc. Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. tevapharm.com ↗
2024-05-13 Boehringer Ingelheim Boehringer Ingelheim expands access to adalimumab-adbm injection, the company's biosimilar to Humira® prnewswire.com ↗
2024-05-10 Celltrion Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost celltrion.com ↗
Show all 227 releases opens the full record — a long page

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Adalimumab-EU ClinicalTrials.gov intervention name — accepted as the source's own label NCT02237729 ↗
Known as Adalimumab “PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗
Known as Humira “PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects” NCT02237729 ↗
Route Subcutaneous “subcutaneous dose” NCT02237729 ↗